Özkan DURU, Hasan Ceyhun MACUN, Esra KOCABAŞ

Vinkristin sülfat ile tedavi edilen transmissible venereal tümörlü köpeklerin serum vasküler endotelyal büyüme faktörü seviyeleri

Amaç: Sunulan çalışmada tümör anjiyogenezisinde önemli bir faktör olan vasküler endotelyal büyüme faktörü’nün (VEGF) transmissible venereal tümör’lü (TVT) köpeklerde serum konsantrasyonlarını belirlemek ve vinkristin sülfat ile tedavide bu faktörün seyrini değerlendirmek amaçlanmıştır. Diğer taraftan VEGF seviyesi ile vinkristin sülfat uygulama sayısı arasındaki ilişki araştırılmıştır. Gereç ve Yöntem: Çalışma materyalini; ovariohisterektomi (OHE) yapılmamış, TVT tanısı konulmuş kangal ve kangal melezi 12 dişi köpek (çalışma grubu), OHE yapılmamış kangal ve kangal melezi sağlıklı 12 dişi köpek (kontrol grubu) oluşturdu. Çalışma grubuna alınan 12 köpekten her tedavi öncesi ve tedavi bittikten 1 hafta sonra kan alındı. Kontrol grubunda yer alan köpeklerden bir kez kan alındı. Bulgular: Çalışma grubunda yer alan vakaların tamamı 3-8 (4,33±1,43) vinkristin sülfat uygulamasıyla tedavi edildi. Hastaların 3’ü 3 uygulamayla, 6’sı 4 uygulamayla, 1’i 5 uygulamayla, 1’i 6 uygulamayla ve 1’i 8 uygulamayla iyileşti. Tedavi öncesi serum VEGF seviyesi ile vinkristin sülfat uygulama sayısı arasında yapılan korelasyon analizinde istatistiksel olarak anlamlı olmayan pozitif korelasyon belirlendi(r =0,051). Çalışma grubundaki köpeklerin tedavi öncesi serum VEGF değeri ile kontrol grubundaki köpeklerin serum VEGF değerleri karşılaştırıldığında, istatistiksel bir fark tespit edilmedi (p=0,160). Öneri: Sonuç olarak TVT’li köpeklerin serum VEGF değerinin sağlıklı köpeklere göre yüksek olmasına rağmen istatistiksel bir fark olmadığı belirlendi. Tedavi öncesi serum VEGF değeri ile uygulama sayısı arasında korelasyon bulunmadı.

Serum vascular endothelial growth factor levels in bitches with canine transmissible venereal tumors treated with vincristine sulphate

Aim: The present study aimed to determine the serum concentrations of vascular endothelial growth factor (VEGF), which is an important factor in tumor angiogenesis, in dogs with transmissible venereal tumor (TVT) and to evaluate the levels of this factor in treatment with vincristine sulphate. On the other hand, the relationship between VEGF level and the number of vincristine sulphate applications was investigated. Materials and Methods: Study material is consisted of twelve Kangal Shepherds and its crossbreds without ovariohysterectomy (OHE) diagnosed with TVT (study group)and 12 healthy Kangal Shepherds and its crossbreds without OHE (control group). Blood was drawn from 12 dogs included in the study group before each treatment and one week after the end of the treatment. Blood was drawn once from the dogs in the control group. Results: All cases in the study group were treated with 3-8 (4,33±1,43) vincristine sulphate administrations. Three of the patients recovered with 3, 6 of the dogs with 4, 1 with 5, 1 with 6 administrations and 1 with 8 weeks of administrations. In the correlation analysis that performed between the pre-treatment serum VEGF level and the number of vincristine sulphate administration, a statistically in significant positive correlation was found (r = 0,051). When serum VEGF values of dogs in the study group were compared with the pre-treatment serum VEGF values of dogs in the control group, no statistical difference was found (p = 0,160). Conclusion: As a result, although serum VEGF values of dogs with TVT were higher than healthy dogs, it was determined that there was no statistical difference. No correlation was found between pre-treatment serum VEGF value and number of applications.

PDF

___

Alaçam E, 2015.Vagina ve vulva tümörleri, In: Karnivorlarda Üreme Organlarının Tümörleri, Ed; Yazar A, Sekizinci Baskı, Medisan Yayınevi, Ankara, Türkiye,pp; 354-356.
Albanese F, Poli A, Millanta F, Abramo F, 2002. Primary cutaneous extragenital canine transmissible venereal tumour with Leishmania neoplasticcells: a further suggestion of histiocytic origin. Vet Dermatol, 13, 243-246.
Amaral AS, Sandra BS, Isabella F, Fonseca LS, et al., 2007.
Cytomorphological characterization of transmissible canine venereal tumour. Rev Port Cienc Vet, 10, 253-260.
Amaral AVC, Mucha F, Oliveria IB, Carvalho CF, et al., 2020.
Primary ocular transmissible venereal tumor in a prepubescent female dog. Acta Sci Vet, 48 (Suppl 1), 476.
Boscos CM, Ververidis HN 2004. Clinical findings, diagnosis and treatment. Scientific proceedings WSVA-FECAVAHMS World Comgress Rhodes, 2, 758-761.
Boscos CM, Ververidis HN, Tondis DK, Stamou AI, et al., 1998.
Ocular involvement of transmissible venereal tumor in a dog. Vet Ophthalmol, 1, 167-170.
Buragohain M, Goswami S 2019. Cytological and histopathological findings of nasal transmissible venereal tumour in a dog. Int J Curr Microbiol App Sci, 8(6),1864-1867.
Çelik LS, Mete UÖ, 2017. Overlerde anjiyogenezi etkileyen faktörler. Arch Med Res, 26(3), 330-341.
Das U, Das AK, 2000. Review of canine transmissible veneral sarcoma. Vet Res Comm, 24, 545-556.
Dass LL, Sahay PN, 1989. Surgical treatment of canine transmissible venereal tumour a retrospective study. Indıan Vet J, 66, 255-258.
Demirer E, Ayten Ö, Taş D, 2014. Angiogenesis and anti-angiogenesis treatments. J Clin Anal Med, 5(1),75-79.
Fathi M, Ashry M, Ali KM, Hassan A, et al., 2018. Clinico-pathological evalutaion and treatment outcomes of canine transmissible veneral tumor using three different protocols. Pak Vet J, 38(2),204-208.
Féo HB, Florez LM, Yamatogi RS, Duzanki AP, et al., 2018.
Does the tumour micro environment after tumorigenesis and clinical response in tranmissible venereal tumour in dogs?. Vet Comp Oncol, 16,370-378.
Ferrara N, 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol, 280,C1358-1366.
Ganguly B, Das U, Das AK, 2013. Canine transmissible venereal tumour: a review. Vet and Comp Oncol, 14(1), 417- 417.
Gram A, Hoffman B, Bass A, Kowalewski MP, 2015. Expression and localization of vascular endothelial growth factor A (VEGFA) and its two receptors (VEGFR1/FLT1 and VGEFR2/FLK1/KDR) in the canine corpus luteum and utero-plecental compartments during pregnancy and at normal and induced parturition. Gen Comp Endocr Volume 223, 1,54-65.
Hicklin DJ, Ellis LM, 2005. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol, 23,1011-1027.
Konukoğlu D, Turhan MS, 2005. Anjiyogenezin temel moleküler mekanizmaları ve tümör anjiyogenezi. Cerrahpaşa J Med, 36,42-48.
Marcos R, Santos M, Marrinhas C, Rocha E, 2006. Cutaneous transmissible veneral tumor without genital involvement in a prepubertal female dog. Vet Clin Pathol, 35, 106-109.
Martins MIM, Souza FF, Gobello C, 2005. The canine transmissible venereal tumor: etiology, pathology, diagnosis and treatment. IVIS, Ithaca NY. A1233-0405.
Morales C, Popdetti M, Roman T, 1990. Treatment of canine transmissible venereal tumour using vincristine sulphate report of 16 cases. Cienc Vet, 12(2-3), 27-33.
Nak D, Kaşıkçı G, 2013. İnfertilite, In: Köpek ve kedilerde doğum ve jinekoloji, Ed;Yazar KAYMAZ, FINDIK, RİŞVANLI, KÖKER, Birinci Baskı, Medipres, Malatya, pp; 223-273.
Nak D, Nak Y, İntaş KS, Tek HB, et al., 2004. Transmissible venereal tumor with mammary gland metastase in a bich.
Vet Bil Derg, 20(1), 99-102.
Özyurtlu N, Bademkıran S, Ünver Ö, Yıldız F, et al., 2008. Dişi bir köpekte transmissible venereal tümörün abdominal ve subkutan inguinal bölgeye metastazı. Dicle Üniv Vet Fak Derg, 1(2), 48-51.
Park MS, Kim Y, Kang MS, Oh SY, et al., 2006. Disseminated transmissible venereal tumor in a dog. J Vet Diagn Invest, 18,130-133.
Parmar KH, Joseph JP, Morabıya KK, Thakre BJ, et al., 2017.
Successfull chemotherapy of canine transmissible veneral tumor in a bitch. IJVSBT, Volume 13, Issue 1, 85-87.
Rezaei M, Azizi S, Shahheidaripour S, Rostami S, 2016. Primary oral and nasal transmissible venereal tumor in a mixbreed dog. Asian Pac J Trop Biomed, 6(5), 443-445.
Serin G, Kıral F, Serin İ, 2008.Serum sialicacid fractions in kangal breed bitches with transmissible venereal tumours. Ankara Üniv Vet Fak Derg, 55, 95-98.
Silva-Hidalgo G, Cota-Guajardo SC, Davıla-Paredes MS, Carcoma-Arechiga NM, et al., 2020. Cerebral metastasis of transmissible veneral tumor after effective chemotherapy in a dog. Turk J Vet Anim Sci,44.
Taşkıran E, Akar H, Erbaş O, 2017. Tümöral anjiyogenezi engelleyen doğal sağlık ürünleri. FNG& Bilim Tıp Transplantasyon Dergisi, 2(1), 1-6.
Uçar M, 2016. Transmissible venereal tumor a review. Kocatepe Vet J 9(3), 230-235.
Uçmak ZG, Kırşan İ, Uçmak M, Bamaç Ö, et al., 2019. Clinical approaches for genital and extragenital metastasis of transmissible venereal tumor in a bitch with ovarian remnant syndrome. Ankara Univ Vet Fak Derg, 66,417-421.
Wergin MC, Hotz BK, 2004. Plasma vascular endothelial growth factor (vegf) measured in seventy dogs with spontoneously occuring tumours. İn vivo, 18, 15-20.
Zayos YR, Malina MAF, Guerra RT, Padilla CR, 2019. Evaluation of a canine transmissible venereal tumour cell line with tumour immunity capacity but without tumorigenic property. J Vet Res, 63,(2)25-233.